Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemisinin + lumefantrine
- Development stage
- Phase 4
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Artemisinin + lumefantrine (commonly administered as the derivative artemether in combination with lumefantrine) is a fixed-dose artemisinin-based combination therapy (ACT) used for the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum. Originally developed by scientists at the Academy of Military Medical Sciences in Beijing, China, and later co-developed and commercialized by Novartis, this combination is a cornerstone of global malaria control. The therapy leverages two distinct mechanisms of action: the fast-acting artemisinin component (such as artemether) rapidly reduces the parasite biomass by generating toxic reactive oxygen species upon activation by heme iron, while the slower-acting, longer-lasting lumefantrine prevents the detoxification of heme into non-toxic hemozoin, clearing residual parasites and preventing recrudescence.
- Brand names
- AcureCoartemFalcynate-LFRiamet
- Other names
- ALartemether + lumefantrineartemether-lumefantrineartemisinin-lumefantrineco-artemether
02
Targets
ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)TPT1 (Translationally-controlled tumor protein)
Beyond the preview
Go deeper on artemisinin + lumefantrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemisinin + lumefantrine.